Studies have suggested that cancer survival rates in the UK are lagging behind other countries by around 10 to 15 years because of lower rates of chemotherapy and radiothe
Draft guidance from NICE has recommended that nine artificial intelligence technologies can be used by NHS England to help plan the treatment of those undergoing external
Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies.
The inaugural Targeted Radiopharmaceuticals Summit US will bring together a worldwide community of specialists to address long-standing challenges in radiopharmac
In our final video from ESMO 2024, web editor Nicole Raleigh spoke with Dr Meredith McKean, a melanoma investigator at the Sarah Cannon Research Institute.